AIM2 and bladder transitional cell carcinoma: To confirm the activation of AIM2 inflammasome in BLCA, we used ODN TTAGGG (A151), an AIM2 inflammasome inhibitor, which can abrogate activation of cytosolic nucleic acid-sensing pathways and prevent AIM2 inflammasome complex formation (Kaminski et al., 2013).